Trends in utilization of glucose- and weight-lowering medications after tirzepatide approval in the United States: a population-based cohort study
In the phase 3a PIONEER (Peptide Innovation for Early Diabetes Therapy) 5 study in people with type 2 diabetes and moderate renal impairment, oral semaglutide demonstrated efficacy in terms of reductions in A1C and body weight, with safety, including renal safety, consistent with the GLP-1 receptor agonist class (53)
While Ozempic can lead to weight loss in Type 2 diabetes patients, results are typically more significant with Wegovy than Ozempic due to Wegovys higher dosage of semaglutide (the same active ingredient found in Ozempic)
When stored at -20C, please use it within 1 month
While using Wegovy, how much weigh you lose and when you start to lose it can depend on many factors, such as other health conditions you have and lifestyle modifications